Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats.
Naoki Kumashiro,Toru Yoshimura,Jennifer L Cantley,Sachin K Majumdar,Fitsum Guebre-Egziabher,Romy Kursawe,Daniel F Vatner,Ioana Fat,Mario Kahn,Derek M Erion,Xian-Man Zhang,Dongyan Zhang,Vara Prasad Manchem,Sanjay Bhanot,Glenn S Gerhard,Kitt F Petersen,Gary W Cline,Varman T Samuel,Gerald I Shulman
DOI: https://doi.org/10.1002/hep.26170
IF: 17.298
2013-01-01
Hepatology
Abstract:Genome-wide array studies have associated the patatin-like phospholipase domain-containing 3 (PNPLA3) gene polymorphisms with hepatic steatosis. However, it is unclear whether PNPLA3 functions as a lipase or a lipogenic enzyme and whether PNPLA3 is involved in the pathogenesis of hepatic insulin resistance. To address these questions we treated high-fat-fed rats with specific antisense oligonucleotides to decrease hepatic and adipose pnpla3 expression. Reducing pnpla3 expression prevented hepatic steatosis, which could be attributed to decreased fatty acid esterification measured by the incorporation of [U-C-13]-palmitate into hepatic triglyceride. While the precursors for phosphatidic acid (PA) (long-chain fatty acyl-CoAs and lysophosphatidic acid [LPA]) were not decreased, we did observe an similar to 20% reduction in the hepatic PA content, similar to 35% reduction in the PA/LPA ratio, and similar to 60%-70% reduction in transacylation activity at the level of acyl-CoA:1-acylglycerol-sn-3-phosphate acyltransferase. These changes were associated with an similar to 50% reduction in hepatic diacylglycerol (DAG) content, an similar to 80% reduction in hepatic protein kinase C epsilon activation, and increased hepatic insulin sensitivity, as reflected by a 2-fold greater suppression of endogenous glucose production during the hyperinsulinemic-euglycemic clamp. Finally, in humans, hepatic PNPLA3 messenger RNA (mRNA) expression was strongly correlated with hepatic triglyceride and DAG content, supporting a potential lipogenic role of PNPLA3 in humans. Conclusion: PNPLA3 may function primarily in a lipogenic capacity and inhibition of PNPLA3 may be a novel therapeutic approach for treatment of nonalcoholic fatty liver disease-associated hepatic insulin resistance. (HEPATOLOGY 2013;57:1763-1772)